- Home
- ACXP vs INAB Comparison
ACXP vs INAB Comparison
Compare ACXP & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- INAB
- Stock Information
- Founded
- ACXP 2017
- INAB 2016
- Country
- ACXP United States
- INAB United States
- Employees
- ACXP N/A
- INAB N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- INAB Health Care
- Exchange
- ACXP Nasdaq
- INAB Nasdaq
- Market Cap
- ACXP 8.4M
- INAB 14.5M
- IPO Year
- ACXP 2021
- INAB 2021
- Fundamental
- Price
- ACXP $0.47
- INAB $2.30
- Analyst Decision
- ACXP Strong Buy
- INAB Strong Buy
- Analyst Count
- ACXP 2
- INAB 2
- Target Price
- ACXP $10.00
- INAB $108.00
- AVG Volume (30 Days)
- ACXP 18.7M
- INAB 170.8K
- Earning Date
- ACXP 08-08-2025
- INAB 08-07-2025
- Dividend Yield
- ACXP N/A
- INAB N/A
- EPS Growth
- ACXP N/A
- INAB N/A
- EPS
- ACXP N/A
- INAB N/A
- Revenue
- ACXP N/A
- INAB N/A
- Revenue This Year
- ACXP N/A
- INAB N/A
- Revenue Next Year
- ACXP N/A
- INAB N/A
- P/E Ratio
- ACXP N/A
- INAB N/A
- Revenue Growth
- ACXP N/A
- INAB N/A
- 52 Week Low
- ACXP $0.30
- INAB $2.05
- 52 Week High
- ACXP $3.33
- INAB $27.30
- Technical
- Relative Strength Index (RSI)
- ACXP 52.38
- INAB 39.46
- Support Level
- ACXP $0.45
- INAB $2.10
- Resistance Level
- ACXP $0.59
- INAB $2.30
- Average True Range (ATR)
- ACXP 0.08
- INAB 0.14
- MACD
- ACXP -0.01
- INAB 0.11
- Stochastic Oscillator
- ACXP 27.06
- INAB 49.56
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.